Product Pipeline

Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel drugs for the treatment of cancer. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.

Myrexis maintains a fully-integrated drug discovery operation designed to identify modulators of novel targets for clinical development.

	IND-Enabling Studies	Safety/Dosing Studies	Efficacy Studies
Azixa™ Brain Cancer
MPC-3100 Cancer
MPC-9528 Cancer
MPI-485520 Cancer and Inflammation
MPI-443803 Brain Cancer
MPI-487109 Cancer